GSK Extends Drug Pipeline Push With Up To €3.7B Merck Deal
GlaxoSmithKline PLC unveiled plans Tuesday to pay up to €3.7 billion ($4.22 billion) to develop an immunotherapy alongside Germany's Merck KGaA, in the U.K. drugmaker's latest play to build out its...To view the full article, register now.
Already a subscriber? Click here to view full article